

AMENDMENTS TO THE CLAIMS

Please replace the claims, including all prior versions, with the listing of claims below.

LISTING OF CLAIMS:

1-21 (canceled).

22. (new): A method of treating, managing or preventing obstructive lung disease comprising:

administering to a patient a pharmaceutical composition comprising an effective amount of mycobacterium w prepared by cell disruption, solvent extraction, or enzymatic extraction.

23. (new): The method of claim 22, wherein the method is for treating, managing or preventing asthma.

24. (new): The method of 23, wherein the method is for delaying attacks of asthma.

25. (new): The method of 23, wherein the method is for reducing the requirement of drugs used to improve lung function during the management of asthma.

26. (new): The method of claim 23, wherein the method is for improving lung function in the presence or absence of other drugs.

27. (new): The method of claim 23, wherein the asthma is bronchial asthma.

28. (new): The method of claim 22, wherein the pharmaceutical composition comprises an admixture of mycobacterium w and constituents of mycobacterium w prepared by cell disruption.

29. (new): The method of claim 22, wherein the pharmaceutical composition comprises constituents of mycobacterium w prepared by cell disruption.

30. (new): The method of claim 28, wherein the constituents of mycobacterium w are prepared by sonication or high pressure fractionometer.

31. (new): The method of claim 29, wherein the constituents of mycobacterium w are prepared by sonication or high pressure fractionometer.

32. (new): The method of claim 22, wherein the pharmaceutical composition comprises constituents of mycobacterium w prepared by solvent extraction.

33. (new): The method of claim 32, wherein the solvent is selected from the group consisting of chloroform, ethanol, methanol, acetone, phenol, isopropyl alcohol, acetic acid, urea and hexane.

34. (new): The method of claim 22, wherein the pharmaceutical composition comprises constituents of mycobacterium w prepared by enzymatic extraction.

35. (new): The method of claim 34, wherein the enzymatic extraction is carried out using lyticase and/or pronase.

36. (new): The method of claim 22, wherein the pharmaceutical composition further comprises an adjuvant.

37. (new): The method of claim 36, wherein the adjuvant is selected from mineral oil, mineral oil and surfactant, Ribi adjuvant, Titer-max, syntax adjuvant formulation, aluminum salt adjuvant, nitrocellulose adsorbed antigen, immune stimulating complexes, Gebru adjuvant, super carrier, elvax 40w, L-tyrosine, monatanide (manide – oleate compound), Adju prime, Squalene, Sodium phthalyl lipopoly saccharide, calcium phosphate, saponin, melanoma antigen and muramyl dipeptide (MDP).

38. (new): The method of claim 22, wherein the pharmaceutical composition further comprises a surfactant.

39. (new): The method of claim 38, wherein the surfactant is polyoxyethylene sorbitan monooleate (Tween 80) or Triton X100.

40. (new): The method of claim 38, wherein the surfactant is present in the pharmaceutical composition in a concentration of up to 0.4%.

41. (new): The method of claim 38, wherein the surfactant is present in the pharmaceutical composition in a concentration of up to 0.1%.

42. (new): The method of claim 22, wherein the pharmaceutical composition further comprises a preservative.

43. (new): The method of claim 42, wherein the preservative is Thiomerosal and is present in a concentration of 0.01% w/v.

44. (new): The method of claim 22, wherein the mycobacterium w is dead mycobacterium w.

45. (new): The method of claim 22, wherein the pharmaceutical composition is in a unit dosage form comprising at least 10^5 mycobacterium w.

46. (new): The method of claim 22, wherein the pharmaceutical composition is in a unit dosage form comprising at least 10^7 mycobacterium w.

47. (new): The method of claim 22, wherein the pharmaceutical composition is in a unit dosage form comprising between 10^8 and 10^9 mycobacterium w.